Our discussions during this presentation will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in Pfizer’s 2009 Annual Report on Form 10-K and in our reports on Form 10-Q and Form 8-K.

These reports are available on our website at www.pfizer.com in the "Investors—SEC Filings" section.
A Revitalized R&D Organization

- Centered on pipeline delivery
- Improving decision-making and clinical development of candidates
- Delivering smarter and more authentic integration of science and business
- Applying a breadth of scientific approaches and technologies to deliver next generation medicines
- Establishing a new standard for engagement and development of world class scientific talent
- Driving a vibrant culture of science, rigorous in nature, innovative by design
Delivering the Benefits of Integration

- Four core R&D Groups
- Chief Scientific Officers lead 20 Research and Biotechnology Units
- Design leverages our strengths in small molecules, vaccines and biologics
- The new Pfizer builds an appealing platform for leading scientific talent

WRD Scientific Leadership Team

Mikael Dolsten
Worldwide R&D

Jose-Carlos Gutierrez-Ramos
Ptx R&D

Rod MacKenzie
Vaccine R&D

Emilio Emini
Biotech Units

Jaume Pons
CTO

Chuck Baum
Clinical Programs

John Hubbard
Development & Strategic Ops

Evan Loh
Drug Safety R&D

Tim Anderson
External R&D Innovation

Tony Coyle
CSO, Open Innovation

Ed Mascioli
CSO, Orphan & Genetic Diseases

Mike Ehlers
CSO, Neuroscience

New CSOs

Legacy Pfizer
Legacy Wyeth
Legacy BBC
Our Operating Model Drives Strong Alignment Between R&D and Commercial BUs

Worldwide R&D

Discovery → Pre-Clinical → Ph 1 → Ph 2 → Ph 3 → Reg / Launch

Business Units

IND FIH PoC

Ongoing dialog with BUs on key product attributes and criteria
- Rationale & key data
- Positioning
- Target product profile
- Differentiation
- Label
- Project plan

Agreed PoC decision analyses tools (Statistical)

Note: Exceptions are Vaccines unit which spans Discovery through Registration and NCE Oncology drugs, which transition to the BU at FIH
Pfizer WRD: Meeting the Challenges

Focused on Three Horizons To Drive Sustained Progress

Horizon 1: Deliver the Portfolio
- Maximize productivity and ROI
- Deep knowledge of pathogenic mechanisms
- Medically differentiated products

Horizon 2: Innovate New Capabilities
- Next generation therapeutics
- Open and external innovation
- Vaccines for all ages and geographies

Horizon 3: R&D Ecosystem of the Future
- Precision Medicine
- Networked, interactive R&D
- Breakthrough productivity
Our Portfolio is Supported by Leading Drug Design Capabilities (e.g., Biologics)

Pfizer leads in cutting-edge technology platforms ...

- Peptides
- ADCs
- Vaccines
- Antibodies
- Therapeutic Proteins
- Vaccines
- Inflammation / Immunology
- Oncology
- Neuroscience / Pain
- Cardiovascular / Metabolic Disease
- Pulmonary Vascular Disease
- Genetic/Orphan diseases
- Retinal Diseases
- Shark IgNARs
- CovX Bodies
- Combinatorial biologics
  - CovX Peptibodies
  - Scorpions
  - Tandem Approaches
  - Lobsters
  - scFv Multimers
  - Shark Jaws
  - SMIPs
  - $\text{V}_{\text{HH}}$ Nanobodies

... And is pursuing technologies of the future
A Bi-functional CovX-Body with two targets

Angiopoietin-2 (Ang-2)

Vascular endothelial growth factor ligand (VEGF)

VEGF and Ang-2 are two growth factors which promote tumor angiogenesis and progression

Inhibition of tumor growth in an animal model by CovX-Body

Note: Dual acting Covxbody candidates for Oncology and Diabetes in preclinical-Phase 1
Crizotinib: A potent and selective oral inhibitor of MET and ALK

... initially being developed for MET mechanism

Academic discovery of new patient segment redefined lung cancer

10-15%\(^1\) of non small cell lung cancer (NSCLC) patients with fusion oncogene ELM4-ALK\(^2\) are unresponsive to conventional EGFR inhibitor\(^1\) treatment

New Phase I trial targeting advanced NSCLC patients harboring ALK rearrangement

Highly effective therapy
Overall response rate = 65%
Disease control rate = 84% at a median of ~24 weeks

Accelerated clinical activities
Initiated Phase 3 trial based on Phase 1 results, bypassing Phase 2 and accelerating development timeline

---

1 Shaw AT et al., J Clin Oncol. 2009; 27:4247-4253
2 Manabu Soda et al., Nature 2007; 448, 561-566
Clinical Outcome for NSCLC Patients After Crizotinib Treatment

Tumor size change in NSCLC patients treated with C-Met/ALK inhibitor

% of best change from baseline vs Treatment Duration (weeks)

-100 -80 -60 -40 -20 0 20 40

Stable Disease

Partial Remission

Complete Remission

Note: Patients in trial composed of 2nd to 4th line. 1st line response to Standard of Care: ~50%, 2nd line: ~10%, 3rd line: 3-5%
Exciting Drug Programs Progressing Toward Proof of Concept

- Growing diabetes portfolio with Long Acting GLP-1 CovX body, OAP peptide drugs and SGLT2 drugs (Ph 1-2)
  - Powerful glucose control, favorable body weight effects and attractive tolerability profile

- First evidence of clinical differentiation of a novel class of Glucocorticoid Receptor drugs in Rheumatoid Arthritis patients (Ph 2)
  - Improved therapeutic index, better activity on RA symptoms with fewer side effects compared to steroids

- Meningococcal serogroup B vaccine for adolescents yielded positive immunogenicity and tolerability data in clinical study (Ph 2)

- Inotuzumab, an Antibody Drug Conjugate for Non-Hodgkin’s Lymphoma, showing strong clinical data (Ph 2)
  - Data supportive of Phase 3 startup

- Monoclonal Antibody against PCSK9 significantly lowers LDL in patients with hypercholesterolemia (Ph 1)
  - Significant lowering of LDL with very favorable safety profile.
  - Under evaluation alone and in combination with statins for patients in whom statins are not sufficient or not tolerated
## Key Late-Phase Portfolio Candidates

### In Registration

<table>
<thead>
<tr>
<th><strong>Celebrex</strong> Chronic Pain</th>
<th><strong>Lyrica</strong> GAD (monotherapy)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sutent</strong> Pancreatic neuroendocrine tumors</td>
<td><strong>Pristiq</strong> Vasomotor Symptoms of Menopause</td>
</tr>
<tr>
<td><strong>Viviant</strong> Osteoporosis Treatment and Prevention</td>
<td><strong>Xiapex</strong> Dupuytren’s Contracture (MAA)</td>
</tr>
<tr>
<td><strong>apixaban</strong> VTE prevention (MAA)</td>
<td><strong>Taliglucerase alfa</strong> Gaucher Disease</td>
</tr>
<tr>
<td><strong>Macugen</strong> Diabetic Macular Edema (MAA)</td>
<td></td>
</tr>
</tbody>
</table>

### Phase 3

<table>
<thead>
<tr>
<th><strong>apixaban</strong> Acute Coronary Syndrome, Venous Thromboembolism Treatment, Atrial Fibrillation</th>
<th><strong>Aprela</strong> (bazedoxefine/conjugated estrogens) Menopausal Vasomotor Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>axitinib</strong> Renal Cell Carcinoma</td>
<td><strong>bapineuzumab</strong> Alzheimer's Disease</td>
</tr>
<tr>
<td><strong>bosutinib</strong> Chronic Myelogenous Leukemia</td>
<td><strong>Eraxis/Vfend</strong> Aspergillosis</td>
</tr>
<tr>
<td><strong>tasocitinib</strong> Rheumatoid Arthritis</td>
<td><strong>Lyrica</strong> Post Operative Pain, Epilepsy Monotherapy, Central Neuropathic Pain due to Spinal Chord Injury, Peripheral Neuropathic Pain</td>
</tr>
<tr>
<td><strong>Dimebon</strong> (latrepirdine) Alzheimer's Disease, Huntington Disease</td>
<td><strong>Moxidectin</strong> River Blindness</td>
</tr>
<tr>
<td><strong>Torisel</strong> Renal Cell Carcinoma</td>
<td><strong>crizotinib</strong> Lung Cancer</td>
</tr>
<tr>
<td><strong>neratinib</strong> Breast Cancer</td>
<td><strong>Prevenar 13 Adult</strong> Infectious Pneumococcal Disease</td>
</tr>
<tr>
<td><strong>PF-299804</strong> Lung Cancer</td>
<td><strong>Thelin</strong> Pulmonary Hypertension</td>
</tr>
<tr>
<td><strong>Sutent</strong> Prostate Cancer, Adjuvant Renal Cell Carcinoma</td>
<td><strong>Zithromax/Chloroquine</strong> Malaria</td>
</tr>
<tr>
<td><strong>tanezumab</strong> OA Signs and Symptoms (On Clinical Hold)</td>
<td></td>
</tr>
</tbody>
</table>